CSBio CSBio

X
[{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Eurostars","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oryzon Genomics"},{"orgOrder":0,"company":"VIVEbiotech","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VIVEbiotech Collaborates with Xyphos Biosciences for Clinical Development Support Of Convertible CAR-T\u2122 Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"VIVEbiotech"},{"orgOrder":0,"company":"Mabxience","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abbott Broadens Access to Cutting-edge Biosimilars in Key Emerging Markets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Mabxience"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreemeent, Abbott will commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa, and mAbxience will develop, manufacture and supply the biosimilar molecules.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Abbott Laboratories

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ORY-1001 (iadademstat) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers.

            Lead Product(s): Iadademstat,Undisclosed

            Therapeutic Area: Oncology Product Name: ORY-1001

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eurostars

            Deal Size: $0.4 million Upfront Cash: Undisclosed

            Deal Type: Funding December 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement covers VIVEbiotech long-term supplying lentiviral vectors for Xyphos’ upcoming clinical trial of its lead convertibleCAR-T™ program. This involves VIVEbiotech manufacturing lentiviral vectors for both preclinical and clinical phases.

            Lead Product(s): Lentiviral vectors,convertible CAR-T cells

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Xyphos Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 04, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY